Sam Brusco, Associate Editor06.07.22
Insulet presented new, positive Omnipod automated insulin delivery system (Omnipod 5) study results for very young children with type 1 diabetes at the American Diabetes Association (ADA) annual meeting that showed significant improvements in time in range (TIR) and reduced HbA1c.
“One of our biggest goals in the development of Omnipod 5 was to ease the burden that type 1 diabetes places on families and caregivers of this vulnerable age group,” Dr. Trang Ly MBBS, FRACP, Ph.D., Insulet senior VP and medical director told the press. “With these preschool extension trial results, we have demonstrated improved glycemic results over the long term for very young children managing diabetes. I’m incredibly proud of this remarkable achievement and know that Omnipod 5 will have a big impact on these families.”
After 12 months of use, average HbA1c was 6.9% compared to 7.4% at baseline. TIR during months 10-12 of use was 67.6% compared to 57.2% during standard therapy. Percent tyime in hypoglycemia was reduced to 1.9% during months 10-12 of use as well.
“I’m delighted to report that the safety and improved glycemic outcomes from the initial three-month pivotal study in pre-school aged children continued for an additional nine months, indicating the potential long-term benefit of the Omnipod 5 System in very young people with type 1 diabetes,” said Dr. Daniel DeSalvo, MD of Baylor College of Medicine. “It is particularly challenging for caregivers to manage diabetes in children under six, given their unpredictable eating habits and activity levels. These results, along with the system’s tubeless form factor and ease of use, make Omnipod 5 an excellent choice for automated insulin delivery in this age group, not only for optimizing glycemic outcomes but for alleviating the burden of diabetes for the entire family.”
“One of our biggest goals in the development of Omnipod 5 was to ease the burden that type 1 diabetes places on families and caregivers of this vulnerable age group,” Dr. Trang Ly MBBS, FRACP, Ph.D., Insulet senior VP and medical director told the press. “With these preschool extension trial results, we have demonstrated improved glycemic results over the long term for very young children managing diabetes. I’m incredibly proud of this remarkable achievement and know that Omnipod 5 will have a big impact on these families.”
After 12 months of use, average HbA1c was 6.9% compared to 7.4% at baseline. TIR during months 10-12 of use was 67.6% compared to 57.2% during standard therapy. Percent tyime in hypoglycemia was reduced to 1.9% during months 10-12 of use as well.
“I’m delighted to report that the safety and improved glycemic outcomes from the initial three-month pivotal study in pre-school aged children continued for an additional nine months, indicating the potential long-term benefit of the Omnipod 5 System in very young people with type 1 diabetes,” said Dr. Daniel DeSalvo, MD of Baylor College of Medicine. “It is particularly challenging for caregivers to manage diabetes in children under six, given their unpredictable eating habits and activity levels. These results, along with the system’s tubeless form factor and ease of use, make Omnipod 5 an excellent choice for automated insulin delivery in this age group, not only for optimizing glycemic outcomes but for alleviating the burden of diabetes for the entire family.”